Cost Benefit Analysis (CBA)

Cost benefit analysis (CBA) is a form of full economic evaluation that compares the total costs of an intervention or program with its total benefits, with both costs and benefits measured in monetary terms. By converting all outcomes to a common monetary unit, CBA allows direct comparison of whether the benefits of an intervention exceed its costs, producing a net benefit (benefits minus costs) or a benefit to cost ratio. CBA is widely used in public policy, environmental regulation, transportation planning, and health care, though its application in health is more controversial than in other sectors because of the challenges of placing monetary values on health outcomes and human life.

CBA provides decision makers with a comprehensive framework for evaluating whether a program or policy is worth its costs from a societal perspective. Unlike cost effectiveness analysis, which measures outcomes in natural units (life years, cases prevented), or cost utility analysis, which uses quality adjusted life years, CBA translates all consequences into money, making it possible to compare interventions across entirely different sectors. This universality is CBA's greatest strength: it can assess whether investing in a new highway, a vaccination program, or a job training initiative provides the greatest net benefit to society. However, the need to monetize health outcomes raises ethical and methodological concerns that researchers must address.

Researchers identify all relevant costs associated with the intervention, including direct costs (personnel, materials, overhead), indirect costs (lost productivity), and intangible costs (pain, suffering). They then identify and monetize all relevant benefits, which may include cost savings from disease prevention, increased productivity from improved health, reduced environmental damage, and increased consumer surplus. Benefits to health are often valued using willingness to pay methods (contingent valuation surveys or discrete choice experiments) or the human capital approach (estimating the economic value of productive life years gained). Future costs and benefits are discounted to present values using an appropriate discount rate (commonly 3% to 7% per year, depending on the guidance followed). The results are expressed as net present value (benefits minus costs), a benefit to cost ratio, or an internal rate of return.

Use CBA when you need to evaluate whether the total benefits of an intervention justify its total costs from a broad societal perspective, particularly when comparing interventions across different sectors. It is standard practice in environmental policy (evaluating clean air regulations), transportation (assessing infrastructure investments), and education (measuring returns to training programs). In health care, CBA is less common than cost effectiveness or cost utility analysis but is used when governments require a formal assessment of costs and benefits (in the United States, for example, Executive Order 12866 requires federal agencies to assess the costs and benefits of significant regulations, including health and safety rules) or when the primary outcome is not a health outcome per se (such as evaluating workplace wellness programs or public health infrastructure investments).

The most contentious issue in CBA is the monetization of health outcomes and human life. Placing a monetary value on a statistical life can raise ethical objections, particularly when the valuation method makes some lives appear worth less: the human capital approach, for example, gives lower values to people with lower or no earnings, such as retirees or the unemployed. Another mistake is omitting important cost or benefit categories, which biases the results. Researchers sometimes fail to conduct sensitivity analyses to test how the results change under different assumptions about discount rates, time horizons, or benefit valuations. Double counting benefits (counting the same benefit under different categories) inflates the apparent value of the intervention. Finally, ignoring distributional consequences (who bears the costs and who receives the benefits) can mask important equity concerns.

A government agency conducts a CBA of a nationwide smoking cessation program. Costs, covering program infrastructure, counseling services, and pharmacotherapy subsidies over five years, total $500 million in present value. Benefits, also in present value, include reduced medical expenditures for smoking related diseases ($2.1 billion), increased worker productivity from fewer smoking related sick days ($800 million), and reduced premature mortality valued using the value of a statistical life ($3.5 billion). The net present value is $5.9 billion, and the benefit to cost ratio is 12.8 to 1. Sensitivity analysis shows that the results remain favorable even when the value of a statistical life is reduced by 50% or the discount rate is increased to 7%.